Arcturus Therapeutics (ARCT) Competitors $12.15 -0.55 (-4.33%) Closing price 04:00 PM EasternExtended Trading$12.14 -0.01 (-0.08%) As of 06:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrendsBuy This Stock ARCT vs. CALT, ETNB, OCUL, AMPH, BGM, AUPH, WVE, GYRE, PAHC, and MLYSShould you be buying Arcturus Therapeutics stock or one of its competitors? The main competitors of Arcturus Therapeutics include Calliditas Therapeutics AB (publ) (CALT), 89bio (ETNB), Ocular Therapeutix (OCUL), Amphastar Pharmaceuticals (AMPH), Qilian International Holding Group (BGM), Aurinia Pharmaceuticals (AUPH), Wave Life Sciences (WVE), Gyre Therapeutics (GYRE), Phibro Animal Health (PAHC), and Mineralys Therapeutics (MLYS). These companies are all part of the "pharmaceutical products" industry. Arcturus Therapeutics vs. Calliditas Therapeutics AB (publ) 89bio Ocular Therapeutix Amphastar Pharmaceuticals Qilian International Holding Group Aurinia Pharmaceuticals Wave Life Sciences Gyre Therapeutics Phibro Animal Health Mineralys Therapeutics Arcturus Therapeutics (NASDAQ:ARCT) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, community ranking, media sentiment, valuation, profitability and analyst recommendations. Do analysts recommend ARCT or CALT? Arcturus Therapeutics currently has a consensus target price of $57.80, suggesting a potential upside of 375.72%. Calliditas Therapeutics AB (publ) has a consensus target price of $39.25, suggesting a potential downside of 1.88%. Given Arcturus Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Arcturus Therapeutics is more favorable than Calliditas Therapeutics AB (publ).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcturus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Calliditas Therapeutics AB (publ) 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has better valuation & earnings, ARCT or CALT? Arcturus Therapeutics has higher earnings, but lower revenue than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcturus Therapeutics$131.27M2.51-$29.73M-$2.53-4.80Calliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62 Does the MarketBeat Community favor ARCT or CALT? Arcturus Therapeutics received 423 more outperform votes than Calliditas Therapeutics AB (publ) when rated by MarketBeat users. Likewise, 66.47% of users gave Arcturus Therapeutics an outperform vote while only 55.10% of users gave Calliditas Therapeutics AB (publ) an outperform vote. CompanyUnderperformOutperformArcturus TherapeuticsOutperform Votes45066.47% Underperform Votes22733.53% Calliditas Therapeutics AB (publ)Outperform Votes2755.10% Underperform Votes2244.90% Do insiders & institutionals believe in ARCT or CALT? 94.5% of Arcturus Therapeutics shares are owned by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 16.6% of Arcturus Therapeutics shares are owned by company insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is ARCT or CALT more profitable? Calliditas Therapeutics AB (publ) has a net margin of -30.18% compared to Arcturus Therapeutics' net margin of -36.39%. Arcturus Therapeutics' return on equity of -22.39% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Arcturus Therapeutics-36.39% -22.39% -14.81% Calliditas Therapeutics AB (publ) -30.18%-212.04%-27.96% Which has more volatility and risk, ARCT or CALT? Arcturus Therapeutics has a beta of 2.36, suggesting that its stock price is 136% more volatile than the S&P 500. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500. Does the media prefer ARCT or CALT? In the previous week, Arcturus Therapeutics had 14 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 14 mentions for Arcturus Therapeutics and 0 mentions for Calliditas Therapeutics AB (publ). Arcturus Therapeutics' average media sentiment score of 0.60 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Arcturus Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Arcturus Therapeutics Positive Calliditas Therapeutics AB (publ) Neutral SummaryArcturus Therapeutics beats Calliditas Therapeutics AB (publ) on 16 of the 19 factors compared between the two stocks. Get Arcturus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARCT vs. The Competition Export to ExcelMetricArcturus TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$329.52M$6.48B$5.35B$8.38BDividend YieldN/A2.66%5.22%4.10%P/E Ratio-5.478.9226.8419.71Price / Sales2.51250.96391.39116.98Price / CashN/A65.8538.2534.62Price / Book1.176.466.794.50Net Income-$29.73M$143.98M$3.23B$248.18M7 Day Performance12.08%3.04%4.07%1.14%1 Month Performance10.45%7.44%12.52%15.18%1 Year Performance-59.30%-2.46%16.83%6.55% Arcturus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARCTArcturus Therapeutics2.9583 of 5 stars$12.15-4.3%$57.80+375.7%-58.4%$329.52M$131.27M-5.47180Gap UpCALTCalliditas Therapeutics AB (publ)N/A$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180ETNB89bio2.8936 of 5 stars$8.11+5.3%$27.25+236.0%+1.0%$1.18BN/A-2.7940Positive NewsOCULOcular Therapeutix4.2502 of 5 stars$7.39+4.7%$16.25+119.9%+20.8%$1.18B$59.65M-5.60230Gap UpAMPHAmphastar Pharmaceuticals4.2514 of 5 stars$24.34+1.0%$32.33+32.8%-41.8%$1.16B$731.97M8.111,620BGMQilian International Holding GroupN/A$11.42+3.5%N/AN/A$1.11B$25.10M0.00298Positive NewsGap UpAUPHAurinia Pharmaceuticals2.4527 of 5 stars$8.12+1.5%$11.50+41.6%+43.6%$1.11B$235.13M-54.13300WVEWave Life Sciences4.4076 of 5 stars$6.60+0.2%$21.17+220.7%+2.5%$1.02B$108.30M-5.95240Positive NewsGap DownGYREGyre Therapeutics0.2757 of 5 stars$10.83+13.6%N/A-21.0%$1.02B$105.76M541.5040PAHCPhibro Animal Health3.5291 of 5 stars$24.50+9.0%$20.00-18.4%+32.1%$992.32M$1.11B51.041,860Positive NewsMLYSMineralys Therapeutics2.7745 of 5 stars$15.01+2.5%$33.00+119.9%+25.7%$973.79MN/A-4.1228 Related Companies and Tools Related Companies Calliditas Therapeutics AB (publ) Alternatives 89bio Alternatives Ocular Therapeutix Alternatives Amphastar Pharmaceuticals Alternatives Qilian International Holding Group Alternatives Aurinia Pharmaceuticals Alternatives Wave Life Sciences Alternatives Gyre Therapeutics Alternatives Phibro Animal Health Alternatives Mineralys Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARCT) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcturus Therapeutics Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcturus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ARCT Stock Free ARCT Stock Alerts